Pharmacokinetics of Cefquinome in Camels

The objective of this study was to investigate the pharmacokinetics of cefquinome following single intramuscular (IM) administration in six healthy male buffalo calves.Cefquinome was administered intramuscularly (2 mg/kg bodyweight) and blood samples were collected prior to drug administration and up to 24 hr after injection. No adverse effects or changes were observed after the IM injection of cefquinome.Plasma concentrations of cefquinome were determined by high-performance liquid chromatography. The disposition of plasma cefquinome is characterized by a monocompartmental open model. The pharmacokinetic parameters after IM administration (mean ± SE) were C max 6.93 ± 0.58 μg/ml, T max 0.5 hr, t ½kα 0.16 ± 0.05 hr, t ½β 3.73 ± 0.10 hr, and AUC 28.40 ± 1.30 μg hr/ml after IM administration. A dosage regimen of 2 mg/kg bodyweight at 24-hr interval following IM injection of cefquinome would maintain the plasma levels required to be effective against the bacterial pathogens with MIC values ≤0.39 μg/ml. The suggested dosage regimen of cefquinome has to be validated in the disease models before recommending for clinical use in buffalo calves.

Section: Pharmacokinetic Parameters (Mean ± Sd) Of Cefquinome In Buffmentioning

confidence: 86%

Section: Pharmacokinetic Parameters (Mean ± Sd) Of Cefquinome In Buffmentioning

confidence: 99%

Pharmacokinetics of a single intramuscular injection of cefquinome in buffalo calves

Venkatachalam

Dumka

Ranjan

2017

“…This has been reported in various species following intramuscular (i.m.) administration, such as in camels (Al Taher, ), rabbits (Hwang et al ., ), sheep (Uney et al ., ), cows (Zonca et al ., ), chickens (Xie et al ., ), mice (Shan et al ., ; Wang et al ., ), and pigs (Zhang et al ., ). But the half‐lives at β ‐phase of i.m.…”

Section: Discussionmentioning

confidence: 99%

In vivo activity of cefquinome against Riemerella anatipestifer using the pericarditis model in the duck

Qiu

Cao

et al. 2015

Cefquinome is a fourth-generation cephalosporin with broad-spectrum antibacterial activity, including activity against enteric gram-negative bacilli such as Riemerella anatipestifer. The pericarditis model was used to examine the pharmacodynamic characteristics of cefquinome against R. anatipestifer. Serum levels of cefquinome following the administration of different doses were determined by LC-MS/MS. Ducks with ca. 10(6) CFU/mL at the initiation of therapy were treated with cefquinome at doses that ranged from 0.0156 to 2 mg/kg of body weight/day (in 3, 6, 12, or 24 divided doses) for 24 h. The percentage of a 24-h dosing interval that the unbound serum cefquinome concentrations exceeded the MIC (fT > MIC) were the pharmacokinetic (PK)-pharmacodynamic (PD) parameter that best correlated with efficacy (R(2) 86.3% for R. anatipestifer, compared with 58.9% for the area under the concentration-time curve/MIC and 10.6% for peak/MIC). A sigmoid Emax model was used to estimate the magnitudes of the %fT > MIC associated with net bacterial stasis, a 1-log10 CFU reduction from baseline, and a 2-log10 CFU reduction from baseline; the corresponding values were (22.5 ± 1.3) %, (35.2 ± 4.5) %, and (42.4 ± 2.7) %. These data showed that treatment with cefquinome results in marked antibacterial effects in vivo against R. anatipestifer and that the host's immunity may also play a key role in the anti-infective therapy process.

“…CFQ could potentially be used for the treatment of many turtle diseases. Pharmacokinetic studies of CFQ have been investigated in salmon (San Martín, Bataglia, Hernández, Quiroz, & Cañon, ), camels (Al‐Taher, ), rabbits (Hwang et al., ), sheep (Tohamy, ; Uney, Altan, & Elmas, ), ducks (Yuan et al., ), ponies (Smiet, Haritova, Heil, Fink‐Gremmels, & Wijnberg, ), cross‐bred wild boars (Liu et al., ), chickens (Xie, Zhang, Wang, & Du, ), pigs (Zhao et al., ), cattle (Shan et al., ), tilapia (Shan et al., ), dogs (Zhang et al., ), buffalo calves (Venkatachalam & Dumka, ), and horses (Uney et al., ). These studies have reported favorable pharmacokinetic features of CFQ, such as good absorption, high bioavailability, and primary elimination via the kidney.…”

Section: Pharmacokinetic Parameters Of Cfq In Red‐eared Sliders (N = mentioning

confidence: 99%

Pharmacokinetics of cefquinome in red‐eared slider turtles (Trachemys scripta elegans) after single intravenous and intramuscular injections

Üney

Altan

Gül

et al. 2017

The purpose of this study was to evaluate the pharmacokinetics of cefquinome (CFQ) following single intravenous (IV) or intramuscular (IM) injections of 2 mg/kg body weight in red-eared slider turtles. Plasma concentrations of CFQ were determined by high-performance liquid chromatography and analyzed using noncompartmental methods. The pharmacokinetic parameters following IV injection were as follows: , and total body clearance (Cl T ) 12.66 ± 2.51 ml hr −1 kg −1. The pharmacokinetic parameters after IM injection were as follows: peak plasma concentration (C max ) 3.94 ± 0.84 μg/ml, time to peak concentration (T max ) 3 hr, t 1/2λz26.90 ± 4.33 hr, and AUC 0-∞ 145 ± 48 μg hr −1 ml −1. The bioavailability after IM injection was 88%. Data suggest that CFQ has a favorable pharmacokinetic profile with a long half-life and a high bioavailability in red-eared slider turtles. Further studies are needed to establish a multiple dosage regimen and evaluate clinical efficacy.